ARS Pharmaceuticals, Inc. SPRY Ratios & Valuation
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Net margin | -200%-184pp | -203.3%-212pp | -56.1%+1,856pp | -42.7%+8,926pp | -16.1%+496,944pp | |
| EBITDA margin | -203%-129pp | -211.3%-157pp | -94.5%+2,259pp | -92.5%+11,242pp | -74%+619,276pp | |
| Free cash flow margin | -177.1%-155pp | -203.1%-218pp | -60.2%+1,732pp | -47.5%+8,798pp | -21.7%+536,098pp | |
| Returns | ||||||
| Return on equity | -136.4%-129pp | -92.3%-95.6pp | -45.9%-23.5pp | -23.6%— | -6.9%— | |
| Return on assets | -64.4%-58.8pp | -50.5%-53.2pp | -27.1%-6.0pp | -17.9%+0.7pp | -5.6%+14.3pp | |
| Return on invested capital | -125.5%-85.0pp | -95.6%-70.2pp | -78.3%-42.5pp | -65%— | -40.4%— | |
| Efficiency | ||||||
| Asset turnover | 0.3×0.0× | 0.2×-0.1× | 0.5×+0.5× | 0.4×+0.4× | 0.4×— | |
| Liquidity | ||||||
| Current ratio | 4.9×-6.1× | 7.3×-7.0× | 6.7×-5.9× | 6.2×-26.7× | 11×-49.9× | |
| Quick ratio | 4.5×-6.1× | 6.7×-7.3× | 6.4×-6.1× | 5.9×-26.9× | 10.6×-50.3× | |
| Cash ratio | 0.5×-1.0× | 1.1×-1.1× | 1.2×-1.2× | 1.1×-4.3× | 1.4×-13.6× | |
| Leverage | ||||||
| Debt-to-equity | 1.6×+1.6× | 0.8×+0.8× | 0.7×+0.7× | 0×0.0× | 0×0.0× | |
| Debt-to-assets | 0.3×+0.3× | 0.3×+0.3× | 0.3×+0.3× | 0×0.0× | 0×0.0× | |
| Per Share | ||||||
| Book value per share | $0.62-73.6% | $1.16-53.8% | $1.49-27.8% | $1.96-12.0% | $2.34+0.6% | |
| Valuation | ||||||
| Market capitalization | $1.05B-48.7% | $1.15B+12.3% | $993.2M-29.3% | $1.65B+101% | $1.23B+25.3% | |
| Enterprise value | $1.12B-42.6% | $1.21B+23.8% | $1.03B-24.4% | $1.6B+104% | $1.19B+28.5% | |
| Price / sales | 10.6×-10.4× | 13.7×+2.2× | 7×-540× | 14.7×-1,628× | 12.7×-98,523× | |
| Price / book | 13×+6.2× | 10.1×+6.1× | 6.7×-0.3× | 8.6×+4.8× | 5.4×+1.0× | |
| EV / sales | 8.8×-6.8× | 14.3×+3.4× | 7.2×-524× | 14.2×-1,555× | 12.3×-92,945× | |
| Free cash flow yield | -22%-20.7pp | -14.9%-16.1pp | -8.7%-5.4pp | -3.2%+2.1pp | -1.7%+3.7pp | |
| Earnings yield | -24.9%-23.8pp | -14.9%-15.7pp | -8.1%-4.6pp | -2.9%+2.5pp | -1.3%+3.8pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do ARS Pharmaceuticals, Inc.'s ratios come from?
- Every ratio is computed from ARS Pharmaceuticals, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
